PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes

Wei Liu, Xiaojun Tian, Ti Wu, Le Liu, Yanghongyun Guo, and Changhua Wang

1Department of Otorhinolaryngology, Head and Neck Surgery, The Second People’s Hospital of Jingzhou City, Jingzhou, 434000 Hubei, China
2Department of Critical Care Medicine, The Second People’s Hospital of Jingzhou City, Jingzhou, 434000 Hubei, China
3Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, 430071 Hubei, China
4Department of Pathology and Pathophysiology, Wuhan University School of Basic Medical Sciences, Wuhan, 430071 Hubei, China

Correspondence should be addressed to Changhua Wang; chwang0525@whu.edu.cn

Received 5 June 2018; Revised 30 September 2018; Accepted 12 November 2018; Published 15 January 2019

Academic Editor: Davide Francomano

Copyright © 2019 Wei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The involvement of phosphodiesterase type 5 (PDE5) in the development of insulin resistance has been reported recently. However, the underlying molecular mechanism remains unclear. The present study aims at investigating the potential impacts of PDE5A on insulin signaling in C2C12 skeletal muscle myotubes and uncover the related mechanism.

Methods. C2C12 myoblasts were differentiated into myotubes. Western blot was performed to detect the levels of proteins and phosphorylated proteins. Glucose uptake was determined by a colorimetric kit. The overexpression or knockdown of specific protein was carried out by infecting the myotubes with adenoviruses carrying cDNA or shRNA corresponding to the targeted protein, respectively.

Results. PDE5A was demonstrated to negatively regulate insulin signaling, evidenced by the opposite effects on the suppression or enhancement of the insulin-stimulated Akt phosphorylation and 2-deoxy-D-glucose (2-DG) uptake in C2C12 myotubes, when PDE5A was overexpressed or knockdown, respectively. Interestingly, PDE5A overexpression led to significantly enhanced, while its knockdown resulted in markedly reduced, endoplasmic reticulum (ER) stress. Inhibition of ER stress improved PDE5A overexpression-induced insulin resistance. In addition, PDE5A was found to suppress proteasome activity. Inhibition of PDE5 by its selective inhibitor icariin restored PDE5A overexpression-induced insulin resistance and mitigated PDE5A overexpression-induced ER stress. Consistently, icariin administration also markedly attenuated the detrimental impacts of PDE5A overexpression on insulin signaling. Conclusions. These results suggest that PDE5A suppresses proteasome activity, which results in ER stress and subsequent insulin resistance in C2C12 myotubes.

1. Introduction

Phosphodiesterase (PDE) is a widely expressed family of metallo-hydrolases containing at least 11 isoforms. Among them, PDE5 catalyzes the breakdown of cGMP into the inactive 5′-GMP resulting in multiple cellular activities [1]. Its inhibition has long been recognized as an efficacious therapeutic option for the treatment of erectile dysfunction [1, 2]. Interestingly, recent studies have suggested that PDE5 inhibitors may be beneficial in treating the patients with hypertension, cardiovascular diseases, diabetes, CNS-related diseases, or cancers [3–5].

Insulin resistance, a hallmark of obesity and diabetes, is a pathophysiological condition in which the insulin action to regulate glucose uptake and lipid metabolism is reduced or even vanished in its target tissues such as skeletal muscles and adipose tissues. Several preclinical and clinical studies have evidenced the protection of PDE5 inhibitors against endothelial dysfunction and myocardial ischemia/reperfusion injury through their anti-inflammatory and antioxidant properties [5]. Although the relief of systemic insulin resistance was not observed in the obesity treated with PDE5 inhibitor [6], recent animal studies and clinic trails have highlighted a possibility that PDE5 inhibition contributes to
the improvement of insulin resistance in the subjects with diabetes [7–9]. Additionally, PDE5 inhibitors display an insulin-like effect on insulin-sensitizing cells such as skeletal muscle cells, adipocytes, and endothelial cells, leading to the attenuation of insulin resistance [10–13]. These studies clearly suggest that PDE5 inhibitors play a critical role in the regulation of insulin signaling. However, the functional role of PDE5 per se is still needed to be further evaluated.

In the present study, we figured out the molecular mechanism underlying PDE5 function on insulin signaling. Our data showed that PDE5 suppressed proteasome activity leading to endoplasmic reticulum (ER) stress and ultimately insulin resistance in C2C12 myotubes. The identification of PDE5 as a novel modulator of insulin signaling should deepen our knowledge and understanding of the molecular mechanism of insulin resistance and the development of type 2 diabetes.

2. Methods

2.1. Cell Culture and Insulin Treatment. C2C12 myoblasts (CRL-1772™) were obtained from the American Type Culture Collection (ATCC, Manassas, USA) and cultured in a growth medium (DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin). Myogenesis was produced as described previously [14]. Briefly, C2C12 myoblasts at 100% confluence were grown in DMEM with 0.1% FBS, 1% P/S, and 50 mmol/L insulin for 72 h. At that time, more than 90% of the cells were differentiated to myotubes. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. To determine insulin signaling pathway, C2C12 myotubes were starved serum overnight and then stimulated with 100 nmol/L insulin for further 10 min.

2.2. Plasmid Construction and Virus Infection. Adenovirus carrying mouse full-length PDE5A cDNA, shRNA against mouse PDE5A, or shRNA scramble control, respectively, was constructed as described previously [15]. Adenovirus encoding β-galactosidase (β-gal) was kindly provided by Drs. Feng Liu and Lily Q. Dong (University of Texas Health Science Center at San Antonio, USA). Overexpression or knockdown of PDE5A in C2C12 myotubes was induced by adenosine infection. In brief, the cells were incubated in a serum-free DMEM containing adenoviruses (MOI:50) for 6 h, and then grown in a growth medium for another 42 h. After forty-eight hours of infection, the cells were ready for experimental study.

2.3. Glucose Uptake Determination. Glucose uptake was measured using Glucose Uptake Assay Kit (Colorimetric) (ab136955, Abcam, Shanghai, CN) according to the manufacturer’s instructions.

2.4. Proteasome Activity Measurement. The chymotrypsin-like activities of the proteasome were measured as described previously [16, 17]. Briefly, the cells were lysed with cytosolic extraction buffer containing 50 mmol/L HEPES, pH 7.5, 20 mmol/L KCl, 5 mmol/L MgCl2, 2 mmol/L ATP, 1 mmol/L DTT, and 0.025% digitonin. The synthetic fluorogenic peptide substrate Suc-LLVY-AMC was used for assaying the chymotrypsin-like activities of 20S proteasome. For assay specificity, 1 μmol/L of proteasome inhibitor MG132 was incubated with the extract. The fluorescence intensity was obtained at an excitation wavelength of 350 nm and emission wavelength of 440 nm by using a fluorescence spectrometer (PerkinElmer precisely LS 55, Billerica, MA, USA).

2.5. Western Blot. Total protein was extracted with the ice-cold lysis buffer containing 50 mmol/L HEPES, pH 7.6, 150 mmol/L NaCl, 1% Triton X-100, 10 mmol/L NaF, 20 mmol/L sodium pyrophosphate, 20 mmol/L β-glycerol phosphate, 1 mmol/L sodium orthovanadate, 10 μg/mL leupeptin, 10 μg/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride. The protein concentration was determined with the BCA (bicinchoninic acid) protein assay (Thermo, Rockford, IL, USA). The samples were mixed with equal volume of 2x SDS-PAGE loading buffer and then heated at 100°C for 10 min. The proteins were separated on SDS-PAGE gel and then transferred onto a PVDF blotting membrane. The membrane was blocked with 5% dry milk, incubated with specific primary antibodies at 4°C overnight, and followed by incubation with secondary antibodies at room temperature for 1 h. Protein bands were detected with an enhanced chemiluminescence (ECL) kit.

2.6. Statistical Analysis. The data are presented as the mean ± SD. Analysis of variance (ANOVA) and Tukey-Kramer post hoc test or Student’s t-test were performed to test the significance of differences between groups. P < 0.05 was considered significant. The figures are representative of at least four independent experiments with the similar results.

3. Results

3.1. PDE5A Negatively Regulated Insulin Signaling in C2C12 Myotubes. To observe the potential impacts of PDE5A on insulin signaling, C2C12 myotubes were infected with adenoviruses carrying mouse PDE5A cDNA or shRNA, respectively. The adenoviruses carrying β-galactosidase or the scramble sequences of PDE5A shRNA were used as controls. Forty-eight hours after infection, the cells were incubated in a serum-free medium overnight and then treated with or without 100 nmol/L insulin for 10 min. As shown in Figure 1, PDE5A overexpression markedly decreased but PDE5A knockdown significantly increased the insulin-stimulated phosphorylation of Akt T308 and its downstream AS160, accompanied with the reduced or enhanced 2-DG uptake, suggesting that PDE5A inhibited insulin signaling in C2C12 myotubes.

3.2. ER Stress-Mediated PDE5A Action on Insulin Signaling in C2C12 Myotubes. As shown in Figures 2(a) and 2(b), PDE5A-overexpressed C2C12 myotubes exhibited the elevated levels of ER stress markers such as CHOP and phosphorylated IRE-1α, as well as the increased expressions of JNK phosphorylation which is believed to be responsible for ER stress-induced insulin resistance. Indeed, PDE5A overexpression significantly increased the phosphorylation of IRS-1 at Ser307, a potential molecular marker for insulin
Consistent with these results, PDE5A knockdown greatly inhibited the expression levels of CHOP, phosphorylated IRE-1α, phosphorylated JNK, and phosphorylated IRS-1, when compared with the scramble control (Figures 2(c) and 2(d)). These results indicate that PDE5A activated ER stress/JNK signaling pathway in C2C12 myotubes.

To further confirm the impacts of PDE5A-induced ER stress on insulin signaling, PDE5A-overexpressed C2C12 myotubes were incubated in a serum-free medium overnight and then treated with or without 10 mmol/L 4-PBA, a selective ER stress inhibitor for 3 h, followed by stimulation with 100 nmol/L insulin for 10 min. We found that 4-PBA administration significantly enhanced the insulin-stimulated phosphorylation of Akt at T308 (Figures 3(a) and 3(b)) and 2-DG uptake (Figure 3(c)) when compared with those in the PDE5A-overexpression group.

Previous studies have evidenced that 4-PBA can sensitize PI3K/Akt signaling and promote glucose uptake in some normal cells including C2C12 myotubes in an ER stress-independent manner [18, 19]. To further demonstrate the involvement of ER stress in PDE5A-induced insulin resistance, STF-083010 (STF), a novel small-molecule inhibitor of IRE1 [20], was used to inhibit IRE1-mediated branch of the unfolded protein response (UPR), which has been recognized as a critical mediator of ER stress-induced insulin resistance in myotubes by activating JNK/IRS-1 pathway [21]. PDE5A-overexpressed C2C12 myotubes were starved serum overnight, treated with or without 60 μmol/L of STF for 3 h, and then stimulated with or without 100 nmol/L

![Figure 1: Effects of PDE5A on insulin signaling in C2C12 myotubes.](image-url)
insulin for additional 10 min. We found that similar to 4-PBA administration, STF treatment significantly increased insulin-stimulated Akt T308 phosphorylation (Figures 3(d) and 3(e)) and 2-DG uptake (Figure 3(f)) when compared with those in the PDE5A-overexpression group.  

Taken together, these results further affirm that ER stress positively mediated PDE5A action on insulin signaling in C2C12 myotubes.

3.3. PDE5A Suppressed the Chymotrypsin-like Proteasome Activity in C2C12 Myotubes. To investigate the impacts of PDE5A on the proteasome activity, C2C12 myotubes were coinfected with adenoviruses carrying GFPu, a proteasome function reporter, and mouse PDE5A cDNA or shRNA, respectively. We found that PDE5A overexpression or knockdown obviously increased or decreased the GFPu protein levels, respectively (Figures 4(a) and 4(b)). Peptidase
activity assays also revealed that the chymotrypsin-like activities of proteasome were significantly reduced or enhanced in PDE5A-overexpressed or -silenced C2C12 myotubes, respectively (Figures 4(c) and 4(d)). These results indicate that PDE5A inhibited the proteasome activities in C2C12 myotubes.

When PDE5A knockdown or control cells were over-expressed with GFPu and then treated with or without 5 μmol/L of proteasome inhibitor MG132 for 6 h, we found that MG132 administration markedly prevented PDE5A knockdown-induced reduction of GFPu protein (Figures 4(e) and 4(f)), suggesting that PDE5A knockdown-reduced GFPu protein levels were attributed to its regulation on proteasome activity.

3.4. Inhibition of PDE5A Reversed Its Impacts on Proteasome Activity, ER Stress, and Insulin Signaling in C2C12 Myotubes.

To elucidate the functional significance of the links among PDE5A, proteasome activity, and ER stress, PDE5 was inhibited by icariin, a cGMP-specific PDE5 inhibitor. C2C12 myotubes cooverexpressed with GFPu and PDE5A were incubated in the presence or absence of 10 μmol/L icariin for 6 h. We found that the GFPu protein levels were significantly suppressed (Figures 5(a) and 5(b)), whereas the chymotrypsin-like activity of proteasome was significantly elevated (Figure 5(c)) in the icariin-treated cells when compared with the cells overexpressed with PDE5A. Icariin treatment also markedly reduced the expressions of CHIP protein, phosphorylated IRE-1α, phosphorylated JNK, and phosphorylated IRS-1 (Figure 6), suggesting a suppression of ER stress/JNK signaling.

When PDE5A-overexpressed C2C12 myotubes were starved serum overnight, and then grown in the presence or absence of 100 nmol/L insulin for 10 min, we found that icariin administration greatly mitigated PDE5A-reduced phosphorylation of Akt at T308 and 2-DG uptake (Figure 7), suggesting that PDE5A inhibition sensitized insulin signaling.

4. Discussion

PDE5 has been found to be expressed in the insulin-sensitizing cells including adipocytes, cardiac myocytes, and skeletal muscle cells [12, 15, 22, 23]. Its specific inhibitors enhance the insulin-stimulated phosphorylation of the signaling molecules such as IRS-1, Akt, mTOR, and MAPK and [11, 23]. These insulin-mimicking effects result in the improvement of glucose metabolism and lipid homeostasis in human skeletal muscle cells and mouse skeletal muscle C2C12 cells [11, 12, 23]. However, it is still unclear how PDE5 per se functions on insulin signaling. In the present study, we showed that PDE5A inhibited insulin signaling.
aggravated ER stress, and impaired proteasome activity. Selective inhibition of ER stress/UPR by 4-PBA and STF or PDE5 by icariin significantly attenuated the inhibitory effects of PDE5A overexpression on the insulin-stimulated Akt phosphorylation and 2-DG uptake. In addition, icariin administration recovered PDE5A-reduced proteasome activity and mitigated PDE5A-exacerbated ER stress. These results provide evidence for the first time that PDE5A could induce insulin resistance by targeting proteasome/ER stress pathway.

Figure 4: Effects of PDE5A on the proteasome activity in C2C12 myotubes. (a) Effects of PDE5A overexpression (OE) on the GFPu protein levels; (b) effects of PDE5A knockdown (KD) on the GFPu protein levels; (c) effects of PDE5A overexpression on the chymotrypsin-like activity of proteasome; (d) effects of PDE5A knockdown on the chymotrypsin-like activity of proteasome. (e) Representative western blots showing the effects of proteasome inhibitor MG132 on the GFPu protein levels; (f) quantification of the GFPu protein levels in (e). N = 4. *P < 0.05, ***P < 0.001 vs. the control group or the indicated group.
ER is responsible for the synthesis, folding, and assembling of the various secretory and membrane proteins. Previous studies have clearly demonstrated the contribution of ER stress to insulin resistance. Under stressful conditions such as obesity and diabetes, the misfolded or unfolded proteins accumulate in the ER lumen, which triggers an UPR or ER stress response leading to insulin resistance through hyperactivation of JNK and subsequent serine phosphorylation of IRS-1 [21, 24]. Our results are consistent with these findings showing the interference of ER stress on insulin signaling. Our results showed that PDE5A positively regulated ER stress and inhibition of ER stress or UPR by its specific inhibitor 4-PBA or STF significantly increased the insulin-stimulated Akt phosphorylation and 2-DG uptake in PDE5A-overexpressed C2C12 myotubes. Thus, ER stress mediates the inhibitory impacts of PDE5A on insulin signaling.

It has been reported that the adaptive UPR plays a predominant role in maintaining the ER function and ER proteostasis through activating ubiquitin-proteasome ERAD (I) [25–27]. In addition, a number of studies have shown the close association between ER proteostasis and insulin resistance [17, 28, 29]. Impaired proteasome activity would exacerbate the accumulation of the unfolded or misfolded proteins in ER lumen ultimately leading to insulin resistance through ER stress/UPR/JNK signaling pathway [17, 28].
Notably, cGMP-dependent protein kinase (PKG) is regulated by PDE5 in various cells and PDE5 inhibition activates PKG to counteract ER stress [5, 22, 30]. Given that the activated PKG is capable of benign proteasome enhancement [31, 32], it should be reasonable to raise the hypothesis that ER stress and UPR could be modulated by PDE5 through its impacts on PKG-dependent proteasome activity.

Icariin is a specific inhibitor of PDE5, suppressing all three PDE5 isoforms [33, 34]. In addition, icariin has been reported to be able to increase the expression levels of some proteasome subunits like proteasome subunit-alpha type 6 and type 2 and reverse the inhibitory impacts of proteasome inhibitor epoxomicin on proteasome activity [35]. Indeed, our results found that PDE5 inhibition by icariin significantly restored PDE5 overexpression-reduced proteasome activity, along with the reduction of ER stress and the improvement of insulin resistance. Combined with our results showing that proteasome inhibitor MG132 restored PDE5A knockdown-reduced GFPu protein levels, our results therefore confirmed the involvement of the proteasome activity in PDE5-induced insulin resistance in C2C12 myotubes.

In summary, we showed that PDE5A-suppressed proteasome activity initiated a series of responses resulting in the blocking of insulin signaling in C2C12 myotubes. This new finding provides a novel mechanism by which PDE5 leads to insulin resistance. Characterization of the mechanism of PDE5-impaired ER proteostasis and its physiological or pathophysiological consequences should undoubtedly deepen our understanding of the development of insulin resistance and related diseases such as obesity and type 2 diabetes.

**Abbreviations**

PDE: Phosphodiesterase
ER: Endoplasmic reticulum

CHOP: CCAAT/enhancer-binding protein homologous protein
IRE-1α: Inositol-requiring enzyme-1α
JNK: c-Jun N-terminal kinase
IRS-1: Insulin receptor substrate-1
2-DG: 2-Deoxy-D-glucose
shRNA: A short hairpin RNA or small hairpin RNA
ERAD: Endoplasmic-reticulum-associated protein degradation
GFPu: Green fluorescence reporter for UPS functionality
PKG: Protein kinase G.

**Data Availability**

All data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare no conflict of interest.

**Authors’ Contributions**

Conceptualization: W.L. and C.W.; Methodology: W.L. and T.W.; Formal Analysis: W.L., T.W., and LL; Investigation: W.L., X.T., T.W., LL, and Y.G.; Writing-Original Draft Preparation: W.L. and C.W.; Supervision: C.W.; Project Administration: C.W.

**Acknowledgments**

The authors thank Dr. Derek Yu (Uskbio Co., Ltd.) for kindly polishing the language of the manuscript.
References

[1] D. P. Rotella, “Phosphodiesterase 5 inhibitors: current status and potential applications,” *Nature Reviews. Drug Discovery*, vol. 1, no. 9, pp. 674–682, 2002.

[2] M. Doumas, A. Lazaridis, N. Katsiki, and V. Athyros, “PDE-5 inhibitors: clinical points,” *Current Drug Targets*, vol. 16, no. 5, pp. 420–426, 2015.

[3] G. Ribaudo, M. Angelo Pagano, S. Bova, and G. Zagotto, “New therapeutic applications of phosphodiesterase 5 inhibitors (PDE5-Is),” *Current Medicinal Chemistry*, vol. 23, no. 12, pp. 1239–1249, 2016.

[4] S. G. Chrysant, “Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension,” *Current Hypertension Reports*, vol. 15, no. 5, pp. 475–483, 2013.

[5] A. Das, D. Durrant, F. N. Salloum, L. Xi, and R. C. Kukreja, “PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer,” *Pharmacol & Therapeutics*, vol. 147, no. 1, pp. 12–21, 2015.

[6] J. E. Ho, P. Arora, G. A. Walford et al., “Effect of phosphodiesterase inhibition on insulin resistance in obese individuals,” *Journal of the American Heart Association*, vol. 3, no. 5, article e001001, 2014.

[7] C. E. Ramirez, H. Nian, C. Yu et al., “Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 100, no. 12, pp. 4533–4540, 2015.

[8] L. Sjögren, J. Olausson, L. Strindberg et al., “Postprandial effects of the phosphodiesterase-5 inhibitor tadalfil in people with well-controlled type 2 diabetes mellitus: a randomized controlled trial,” *Diabetic Medicine*, vol. 33, no. 9, pp. 1299–1301, 2016.

[9] A. Aversa, “Systemic and metabolic effects of PDE5-inhibitor drugs,” *World Journal of Diabetes*, vol. 1, no. 1, pp. 3–7, 2010.

[10] H. M. Yu, H. K. Chung, K. S. Kim, J. M. Lee, J. H. Hong, and K. S. Park, “PDE 5 inhibitor improves insulin sensitivity by enhancing mitochondrial function in adipocytes,” *Biochemical and Biophysical Research Communications*, vol. 493, no. 1, pp. 631–636, 2017.

[11] C. Crescioli, N. Sturlí, M. Sottili, P. Bonini, A. Lenzi, and L. di Luigi, “Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells,” *Journal of Endocrinological Investigation*, vol. 36, no. 11, pp. 1020–1026, 2013.

[12] S. Sabatini, P. Sgrò, G. Duranti, R. Ceci, and L. di Luigi, “Tadalafil alters energy metabolism in C2C12 skeletal muscle cells,” *Acta Biochimica Polonica*, vol. 58, no. 2, pp. 237–241, 2011.

[13] C. Mammi, D. Pastore, M. F. Lombardo et al., “Sildenafil reduces insulin-resistance in human endothelial cells,” *PLoS One*, vol. 6, no. 1, article e14542, 2011.

[14] R. Conejo, A. M. Valverde, M. Benito, and M. Lorenzo, “Insulin produces myogenesis in C2C12 myoblasts by induction of NF-kappaB and downregulation of AP-1 activities,” *Journal of Cellular Physiology*, vol. 186, no. 1, pp. 82–94, 2001.

[15] M. Zhang, N. Koitabashi, T. Nagayama et al., “Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes,” *Cellular Signalling*, vol. 20, no. 12, pp. 2231–2236, 2008.

[16] Y. Zhang, M. Ye, L. J. Chen, M. Li, Z. Tang, and C. Wang, “Role of the ubiquitin-proteasome system and autophagy in regulation of insulin sensitivity in serum-starved 3T3-L1 adipocytes,” *Endocrine Journal*, vol. 62, no. 8, pp. 673–686, 2015.

[17] M. Ye, H. Qiu, Y. Cao et al., “Curcumin improves palmitate-induced insulin resistance in human umbilical vein endothelial cells by maintaining proteostasis in endoplasmic reticulum,” *Frontiers in Pharmacology*, vol. 8, p. 148, 2017.

[18] H. Hu, L. Li, C. Wang et al., “4-Phenylbutyric acid increases GLUT4 gene expression through suppression of HDAC5 but not endoplasmic reticulum stress,” *Cellular Physiology and Biochemistry*, vol. 33, no. 6, pp. 1899–1910, 2014.

[19] H. Fakhoury, S. Osman, N. Ghazale, N. Dahnah, M. el-Sibai, and A. Kanaan, “Enhanced glucose uptake in phenylbutyric acid-treated 3T3-L1 adipocytes,” *Cell and Tissue Biology*, vol. 12, no. 1, pp. 48–56, 2018.

[20] I. Papandreou, N. C. Denko, M. Olson et al., “Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma,” *Blood*, vol. 117, no. 4, pp. 1311–1314, 2011.

[21] L. Salvadó, X. Palomer, E. Barroso, and M. Vázquez-Carrera, “Targeting endoplasmic reticulum stress in insulin resistance,” *Trends in Endocrinology and Metabolism*, vol. 26, no. 8, pp. 438–448, 2015.

[22] A. Armani, V. Marzolla, G. M. Rosano, A. Fabbri, and M. Caprio, “Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?,” *Trends in Endocrinology & Metabolism*, vol. 22, no. 10, pp. 404–411, 2011.

[23] F. Marampon, C. Antinozzi, C. Corinaldesi et al., “The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism,” *Endocrine*, vol. 59, no. 3, pp. 602–613, 2018.

[24] U. Ozcan, Q. Cao, E. Yilmaz et al., “Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes,” *Science*, vol. 306, no. 5695, pp. 457–461, 2004.

[25] R. Inagl, Y. Ishimoto, and M. Nangaku, “Proteostasis in endoplasmic reticulum-new mechanisms in kidney disease,” *Nature Reviews. Nephrology*, vol. 10, no. 7, pp. 369–378, 2014.

[26] E. Fujita, Y. Kouroku, A. Isoai et al., “Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD (I) and autophagy/lysosome ERAD (II),” *Human Molecular Genetics*, vol. 16, no. 6, pp. 618–629, 2007.

[27] M. Kondratyev, A. Avezov, M. Shenkman, B. Groisman, and G. Z. Lederkremer, “PERK-dependent compartmentalization of ERAD and unfolded protein response machineries during ER stress,” *Experimental Cell Research*, vol. 313, no. 16, pp. 3395–3407, 2007.

[28] A. L. Estrada, W. M. Hudson, P. Y. Kim et al., “Short-term changes in diet composition do not affect in vivo hepatic protein synthesis in rats,” *American Journal of Physiology. Endocrinology and Metabolism*, vol. 314, no. 3, pp. E241–E250, 2018.

[29] A. Baicenanu, P. Mesdom, M. Lagouge, and F. Foufelle, “Endoplasmic reticulum proteostasis in hepatic steatosis,” *Nature Reviews. Endocrinology*, vol. 12, no. 12, pp. 710–722, 2016.

[30] W. Gong, Q. Duan, Z. Cai et al., “Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure,” *British Journal of Pharmacology*, vol. 170, no. 7, pp. 1396–1409, 2013.

[31] P. P. Rainer and D. A. Kass, “Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G,” *Cardiovascular Research*, vol. 111, no. 2, pp. 154–162, 2016.
[32] M. J. Ranek, E. J. M. Terpstra, J. Li, D. A. Kass, and X. Wang,
“Protein kinase g positively regulates proteasome-mediated
degradation of misfolded proteins,” Circulation, vol. 128,
no. 4, pp. 365–376, 2013.

[33] Z. C. Xin, E. K. Kim, C. S. Lin et al., “Effects of icariin on
cGMP-specific PDE5 and cAMP-specific PDE4 activities,”
Asian Journal of Andrology, vol. 5, no. 1, pp. 15–18, 2003.

[34] R. Rahimi, S. Ghiasi, H. Azimi, S. Fakhari, and M. Abdollahi,
“A review of the herbal phosphodiesterase inhibitors; future
perspective of new drugs,” Cytokine, vol. 49, no. 2, pp. 123–
129, 2010.

[35] D. Y. Zhu, R. Cui, Y. Y. Zhang, H. Li, L. M. Zhou, and
Y. J. Lou, “Involvement of ubiquitin-proteasome system in
icariin-induced cardiomyocyte differentiation of embryonic
stem cells using two-dimensional gel electrophoresis,” Journal
of Cellular Biochemistry, vol. 112, no. 11, pp. 3343–3353, 2011.